Skip to main content
Lupus Core Dataset for Research
  • EurekAlert!
SLE is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person – giving rise to marked heterogeneity in not only manifestations, but also in disease course and treatment response. To support better understanding of the disease, researchers have suggested using “big data”.
Physical Therapy Underprescribed
  • MedPage Today
Just one patient in six was referred for physical therapy (PT) within 15 days of being treated for knee pain at one major U.S. health system, researchers found, despite nearly universal consensus that PT should be recommended in most cases.
Study of 90 Still's Dz pts w/ lung disease from AIDA network - mean age 36 yr; 36% male (13% from pediatrics). Lung find

Dr. John Cush RheumNow

11 months 1 week ago
Study of 90 Still's Dz pts w/ lung disease from AIDA network - mean age 36 yr; 36% male (13% from pediatrics). Lung findings: pleuritis 72%, parenchymal 34%, ARDS 9.5% & pulm HTN 2.3%. Parenchymal involvement assoc w/ sore throat, pericarditis, higher systemic score, but not https://t.co/4YIx2BwADe
AbbVie announces positive topline results from a 2nd Phase 3 UP-AA Trial evaluating Upadacitinib in Alopecia Areata (AA)

Dr. John Cush RheumNow

11 months 1 week ago
AbbVie announces positive topline results from a 2nd Phase 3 UP-AA Trial evaluating Upadacitinib in Alopecia Areata (AA) - w/ 45% and 55% of severe AA pts rx w/ UPA 15 mg and 30 mg, achieving a SALT score ≤ 201 (80% or more scalp hair coverage) at week 24 https://t.co/8p1FvJx0s0
Researchers at the Icahn School of Medicine at Mount Sinai have found that prenatal exposure to acetaminophen may increase the risk of neurodevelopmental disorders, including autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD), in children.
Rapid rituximab infusions are safe & efficient. Metanalysis of 7 RCTs, 538 pts w/ autoimmune/rheumatic dz, showed i

Dr. John Cush RheumNow

11 months 2 weeks ago
Rapid rituximab infusions are safe & efficient. Metanalysis of 7 RCTs, 538 pts w/ autoimmune/rheumatic dz, showed infusions(RTX 1000 mg) of 90-120 min (w/ premedication) had low risk (3-15%) of mild (Grades 1, 2) infusion Rxns; only 6 Grade 3 Rxns https://t.co/uVKuhhc80F https://t.co/NIMMhgIRzH
FDA has granted Soligenix "Orphan Drug Designation" to study dusquetide in the treatment of Behçet's dz, based on an 8

Dr. John Cush RheumNow

11 months 2 weeks ago
FDA has granted Soligenix "Orphan Drug Designation" to study dusquetide in the treatment of Behçet's dz, based on an 8 patient proof of concept Phase 2a trial. Not yet FDA approved, dusquetide is a short peptide innate defense regulator (IDR). Behcets affects 18K in USA and https://t.co/RzzVuQ6bAB
Single-center Retrospective study of 4,736 RA, propensity matched 509 w/ RA-ILD vs 509 without ILD. In multivariate ana

Dr. John Cush RheumNow

11 months 2 weeks ago
Single-center Retrospective study of 4,736 RA, propensity matched 509 w/ RA-ILD vs 509 without ILD. In multivariate analysis RF positivity was an independent risk factor for RA-ILD (adj OR = 1.5) w/ signif nonlinear relationship observed, risk threshold @60 IU/mL Paradoxical https://t.co/0XtWnIsbmK
Telitacicept, a BLyS (BAFF)/APRIL dual-target fusion drug, announced it has met the primary endpoint in its Phase III cl

Dr. John Cush RheumNow

11 months 2 weeks ago
Telitacicept, a BLyS (BAFF)/APRIL dual-target fusion drug, announced it has met the primary endpoint in its Phase III clinical trial in treating primary Sjögren's syndrome (pSS) in China. Primary endpoint was the change in ESSDAI score at Week 24. https://t.co/afOgpGLdV1 https://t.co/9EKbbrCgTL
TriNetX database study shows Beta blocker use assoc w/ more hip replacements (THA). 23K propensity matched pts (mean age

Dr. John Cush RheumNow

11 months 2 weeks ago
TriNetX database study shows Beta blocker use assoc w/ more hip replacements (THA). 23K propensity matched pts (mean age 69) on or off BB compared. After 3 yrs BB use was assoc w/ higher risk of THA (HR 1.49; 1.4–1.59), esp w/ alpha-BBs (HR 1.64) https://t.co/W6ocMYI653 https://t.co/EiQ4WH94cD
New IDSA recommendation: In hospitalized on systemic steroids w/ severe, critical, progressing COVID-19, when baricitini

Dr. John Cush RheumNow

11 months 2 weeks ago
New IDSA recommendation: In hospitalized on systemic steroids w/ severe, critical, progressing COVID-19, when baricitinib or tocilizumab are not available, IDSA guideline panel suggests infliximab. https://t.co/ZCkkZXUDpi https://t.co/gbgkvj5R8Y
The global incidence of autoimmune diseases among children has increased over the past few decades. A study published August 21st in the open-access journal PLOS Medicine by Ju-Young Shin at Sungkyunkwan University, Republic of Korea, and colleagues suggests that early life antibiotic exposure is not associated with an increased risk of autoimmune diseases in children.
Sjogrens Graduates (8.22.2025)
×